@misc{oai:repo.qst.go.jp:00065301,
 author = {Yamada, Shigeru and Shinoto, Makoto and Oonishi, Kazuhiko and Imada, Hiroshi and Yasuda, Shigeo and Kamada, Tadashi and Tsujii, Hirohiko and 山田 滋 and 篠藤 誠 and 大西 和彦 and 今田 浩史 and 安田 茂雄 and 鎌田 正 and 辻井 博彦},
 month = {Sep},
 note = {The Heavy Ion Medical Accelerator in Chiba (HIMAC) is the world first heavy ion accelerator complex dedicated to medical use in a hospital environment. Carbon ion therapy offers the potential advantages of improved dose localization and enhanced biological effects. It has been suggested that carbon ion therapy is effective against radioresistant pancreatic cancer. In April 2000, clinical studies examining the treatment of pancreatic cancer with carbon ions were begun at the HIMAC. As of February 2010, 48 patients treated with preoperative carbon ion radiotherapy and 89 patients treated for locally advanced pancreatic cancer were enrolled into the clinical trials. Both protocols are still ongoing. The interim results of these clinical trials suggest that carbon ion radiotherapy provides good local control and offers a survival advantage for patients with otherwise hard to cure pancreatic cancer, without unacceptable morbidity., The KI-NIRS Joint Symposium on Ion-Radiation Sciences},
 title = {Carbon Ion Radiotherapy for Pancreatic Cancer},
 year = {2010}
}